ARTICLE | Clinical News
MIV-310: Began Phase IIa trial
October 29, 2001 8:00 AM UTC
Medivir AB (SSE:MVIR), Huddinge, Sweden Product: MIV-310 Business: Infectious diseases Therapeutic category: Viral replication Target: HIV reverse transcriptase (RT) Description: Nucleoside anal...